DnaJ heat shock protein family (Hsp40) member A2Genealiases: CPR3 · DJ3 · DJA2 · DNAJ · DNJ3 · HIRIP4
Q-omics provides the consensus-scored DNAJA2 profile across patient tissues and cancer cell-line models. DNAJA2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DNAJA2 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, DNAJA2 protein abundance shows 23,746 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, THCA, and CCRCC as cancer lineages where DNAJA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJA2 survival associations across molecular data types. DNAJA2 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJA2 RNA expression–survival associations across cancer types. High DNAJA2 expression shows unfavorable associations in HNSC, LGG, PAAD and LIHC, but favorable associations in KIRC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DNAJA2 RNA expression.
This table summarizes DNAJA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DNAJA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJA2 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, CHOL, COAD and KIRP. The THCA box plot shows higher DNAJA2 RNA expression in normal versus tumor tissue (log2 FC = −0.531, t-test p < 0.001).
This table shows molecular features associated with DNAJA2 in patient tissues and cancer cell lines. In patient samples, DNAJA2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
